1. Home
  2. MASS vs ACRS Comparison

MASS vs ACRS Comparison

Compare MASS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 908 Devices Inc.

MASS

908 Devices Inc.

HOLD

Current Price

$9.33

Market Cap

498.1M

Sector

Health Care

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

SELL

Current Price

$3.33

Market Cap

529.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MASS
ACRS
Founded
2012
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
498.1M
529.9M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
MASS
ACRS
Price
$9.33
$3.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
12
Target Price
★ $14.00
$10.27
AVG Volume (30 Days)
364.9K
★ 2.7M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 125.47
69.01
EPS
N/A
★ N/A
Revenue
★ $56,197,000.00
$1,683,000.00
Revenue This Year
$23.13
N/A
Revenue Next Year
$18.66
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.03
$2.34
52 Week High
$13.35
$6.60

Technical Indicators

Market Signals
Indicator
MASS
ACRS
Relative Strength Index (RSI) 36.12 36.10
Support Level $6.20 $3.24
Resistance Level $11.16 $3.44
Average True Range (ATR) 0.90 0.28
MACD -0.24 0.00
Stochastic Oscillator 5.66 4.02

Price Performance

Historical Comparison
MASS
ACRS

About MASS 908 Devices Inc.

908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: